1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Tinavi Medical Technologies Co., Ltd. Class A

Tinavi Medical Technologies Co., Ltd. Class A

SSSE:688277
15.62
CNY
+0.68
(+4.55%)
-0.44EPS
7.98BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.39
1.28
0.16
0.16
0.24
0.3
0.59
0.35
0.37
0.37
0.47
0.4
0.61
0.57
Basic EPS, GAAP
0.21
-0.52
-0.1
-0.16
0.07
- -
-0.08
-0.14
-0.19
-0.26
-0.35
-0.27
-0.4
-0.4
Free Cash Flow per Basic Share
-0.14
-1.13
0.26
-0.22
- -
-0.03
- -
-0.49
-0.75
-0.35
-0.88
-0.3
-0.18
- -
Dividend per Share
0.01
0.02
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.02
0.02
0.02
Book Value per Share
0.19
0.33
1.03
0.86
1
3
1.55
2.38
2.4
2.49
2.75
2.82
2.6
2.56
Tangible Book Value per Share
0.17
0.33
1.03
0.86
1
2.99
1.55
2.37
2.38
2.47
2.72
2.72
2.48
2.42
Basic Weighted Avg Shares
30
30
154
161
310
418
387
389
421
425
447
449
457
460
Sales/Revenue/Turnover
42
39
24
26
73
127
230
136
156
156
210
179
279
263
Operating Margin (%)
-9.58
-50.92
-110.07
-146.81
10.37
7.91
-19.51
-52.39
-66.35
-93.71
-94.17
-73.39
-51.56
-66.09
Depreciation Expense
2
2
2
2
1
4
8
8
35
45
41
39
45
- -
Net Income, GAAP
6
-16
-15
-26
22
-1
-31
-54
-80
-111
-156
-121
-183
-183
Effective Tax Rate (%)
22.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
15.1
-40.66
-64.44
-100.59
29.56
-0.68
-13.49
-40.08
-51.23
-70.8
-74.46
-67.73
-65.54
-69.55
Working Capital
24
48
189
148
138
454
431
700
394
215
322
281
279
269
LT Debt
- -
- -
- -
- -
- -
- -
- -
17
48
62
161
151
158
146
Total Equity
30
53
163
137
169
574
596
1,027
1,068
1,118
1,238
1,280
1,226
1,223
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-38.24
-14.29
-17.15
14.68
-0.24
-5.39
-6.89
-7.98
-10.79
-13.71
-9.67
-14.89
-14.65

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
39
37
43
LT Borrowings
154
150
143
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
456
456
466
Market Capitalization
6,927
10,410
7,976

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
443
369
415
Cash, Cash Equivalents & STI
306
208
246
Accounts Receivable, Net
35
49
45
Inventories
47
54
68
Total Current Liabilities
164
130
146
Payables & Accruals
- -
- -
- -
ST Debt
39
37
43
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.11%
3.72%
-4.23%
Free Cash Flow
-5,067.01%
14.75%
-40.24%
Net Income, GAAP
352.58%
30.97%
50.87%
Sales/Revenue/Turnover
39.7%
18.09%
55.9%
Total Cash Common Dividend
- -
- -
-20.78%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29
29
34
87
179
2025
59
67
- -
91
279
2026
53
53
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.08
-0.07
-0.1
-0.27
2025
-0.03
-0.1
- -
-0.15
-0.4
2026
-0.1
-0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
0.01
- -
0.02
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jin Xu
Full Time Employees
334
Sector
Health technology
Industry
Medical specialties
Address
Building 7 Beijing BE China 100096
IPO Date
Jul 7, 2020
Website
tinavi.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
TINAVI Medical Technologies Co., Ltd. (688277.SS) develops and manufactures orthopedic surgical robots and related medical navigation systems for spine and trauma surgeries. The company offers core products including the TianJi Robot surgical system for precise orthopedic procedures; orthopedic navigation systems supporting preoperative planning, intraoperative navigation, and postoperative verification; and associated consumables such as disposable instruments and software modules. These solutions integrate advanced imaging, AI-driven trajectory planning, and robotic arm control to enhance surgical accuracy, reduce radiation exposure, and improve patient outcomes in minimally invasive operations. Founded in 2005 and headquartered in Beijing, China, TINAVI operates primarily in the medical robotics industry, targeting hospitals, surgical centers, and healthcare providers in the Asia-Pacific region with expanding presence in Europe and North America. The company serves segments including spine surgery, orthopedics, and neurosurgery, with a focus on high-precision navigation for complex procedures. In recent developments, TINAVI expanded its product portfolio with enhancements to the TianJi-C orthopedic robot system, achieving regulatory approvals for broader indications in trauma and deformity corrections as of 2024. The company secured strategic partnerships with leading medical institutions for clinical trials and adoption, alongside a significant funding round in late 2024 to support R&D in AI-integrated robotics. No major acquisitions or name changes reported in the last two years, though operational scale-up included new manufacturing facilities to meet growing demand in domestic and international markets.